Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

被引：0
作者：
Kelvin Yi Chong Teo
Wei Yan Ng
Shu Yen Lee
Chui Ming Gemmy Cheung
机构：
[1] Singapore Eye Research Institute,Department of Ophthalmology
[2] Singapore National Eye Centre,undefined
[3] Duke-NUS Graduate Medical School,undefined
[4] Yong Loo Lin School of Medicine,undefined
[5] National University of Singapore,undefined
来源：
Drugs | 2016年 / 76卷
关键词：
Bevacizumab; Retinal Pigment Epithelium; Ranibizumab; Well Correct Visual Acuity; Aflibercept;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.
引用
收藏
页码：1119 / 1133
页数：14
相关论文
共 407 条
[71]  
Pang CP(2015)Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome Retina. 151 529-534
[72]  
Okamoto N(2011)Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment Am J Ophthalmology. 56 5794-5800
[73]  
Tobe T(2015)Subfoveal choroidal thickness changes following anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization Invest Ophthalmol Vis Sci. 7 335-339
[74]  
Hackett SF(2016)Macular Bruch’s membrane holes in highly myopic patchy chorioretinal atrophy Am J Ophthalmol. 118 2521-2523
[75]  
Ozaki H(2014)Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study Int J Ophthalmol. 96 1068-1072
[76]  
Vinores MA(2011)Myopic choroidal neovascularization Ophthalmology. 6 1885-1894
[77]  
LaRochelle W(2012)Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia Br J Ophthalmol. 23 887-898
[78]  
Moriyama M(2012)Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naive myopic choroidal neovascularization Clin Ophthalmol. 54 2115-2122
[79]  
Ohno-Matsui K(2013)Choroidal thickness after treatment for myopic choroidal neovascularization Eur J Ophthalmol. 89 70-75
[80]  
Futagami S(2013)Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization Invest Ophthalmol Vis Sci. 88 e136-108
3456789101112